文献速递炎症性肠病

乌司奴单抗治疗溃疡性结肠炎患者真实世界有效性与安全性的Meta分析

Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2023-01-16

该系统综述与随机效应Meta分析纳入19项观察性研究共3786例溃疡性结肠炎患者,评估乌司奴单抗真实世界有效性与安全性。超过92%患者既往使用过生物制剂,第8周临床缓解率45.4%,第12-16周43.8%,第6个月44.6%,第12个月50.6%;结肠切除、不良事件、严重不良事件及严重感染发生率分别为每100患者年4.8、7.9、0.8和0.3。作者认为该Meta分析证实乌司奴单抗在高度难治性溃疡性结肠炎人群中有效且安全。

要点

  • 第8、12-16周、6个月、12个月临床缓解率分别为45.4%、43.8%、44.6%、50.6%。
  • 第12个月内镜改善率58.2%,近30%患者需剂量递增,其中40%有效。
  • 结肠切除、不良事件、严重不良事件、严重感染发生率分别为每100患者年4.8、7.9、0.8、0.3。

核心结论

  • 该Meta分析证实乌司奴单抗在高度难治性溃疡性结肠炎人群中有效且安全。

研究设计与样本

  • 系统检索截至2022年9月的电子数据库,纳入评估乌司奴单抗治疗溃疡性结肠炎的观察性研究,采用随机效应模型计算合并效应量(百分比或发生率)。
  • 共纳入19项研究、3786例患者;超过92%患者既往接受过任何生物制剂,61.1%使用过抗TNF药物和维得利珠单抗,16.4%使用过任何生物制剂和托法替布。

主要发现

  • 第8周、第12-16周、第6个月和第12个月临床缓解率分别为45.4%(95%CI:30.1%-60.6%)、43.8%(38.4%-49.2%)、44.6%(35.9%-53.3%)和50.6%(36.3%-64.8%)。
  • 第8周、第12-16周、第6个月和第12个月应答率分别为61.2%、59.4%、65.2%和76.8%。
  • 第8周、第12-16周、第6个月和第12个月无激素缓解率分别为18.7%、36.8%、34.5%和39%。
  • 第12个月内镜改善率为58.2%;近30%患者需剂量递增,其中40%有效。
  • 结肠切除、不良事件、严重不良事件和严重感染的发生率分别为每100患者年4.8、7.9、0.8和0.3。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence on real-world outcomes of ustekinumab for ulcerative colitis (UC) patients is needed. AIMS: To summarise evidence on the real-world outcomes of ustekinumab for UC and conduct a meta-analysis of effectiveness and safety data. METHODS: A systematic search was conducted through September 2022 in electronic databases for observational studies evaluating ustekinumab for UC. A random-effects meta-analysis model was used to calculate the pooled effect sizes (percentages or incidence rates [IRs]) of effectiveness and safety outcomes. RESULTS: In all, 19 studies were included with 3786 patients. More than 92% of patients were previously treated with any biologic, 61.1% with both anti-TNF and vedolizumab and 16.4% with any biologic and tofacitinib. Clinical remission was achieved in 45.4% at week 8 (95% CI: 30.1%-60.6%), 43.8% (38.4%-49.2%) at weeks 12-16, 44.6% (35.9%-53.3%) at month 6, and 50.6% (36.3%-64.8%) at month 12. Response was achieved in 61.2%, 59.4%, 65.2% and 76.8% at weeks 8, 12-16, month 6 and 12, respectively. CS-free remission was achieved in 18.7%, 36.8%, 34.5% and 39% at weeks 8, 12-16, month 6 and 12, respectively. Overall, 58.2% of patients had endoscopic improvement at month 12. Almost 30% of the patients needed dose escalation, which was effective in 40% of these patients. The IRs of colectomy, adverse events (AEs), serious AEs and serious infections were 4.8, 7.9, 0.8 and 0.3 per 100 patient-years, respectively. CONCLUSIONS: This meta-analysis confirms the effectiveness and safety of ustekinumab in a highly treatment-refractory population of UC patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Taxonera C, Olivares D, López-García ON, et al. Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2023. PMID: 36645145. doi:10.1111/apt.17386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。